Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Antigen-dependent costimulation to improve T-cell therapy for cancer.
Authors
Christopher C. DeRenzo
Center for Cell and Gene Therapy, Texas Children's Cancer Center, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX
Christopher C. DeRenzo, Phuong Nguyen, Stephen Gottschalk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Adoptive T-cell therapy: Modified and Unmodified Cells
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 151)
DOI
10.1200/JCO.2017.35.7_suppl.151
Abstract #
151
Poster Bd #
G10
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma.
First Author: Sarah Nikiforow
Poster
2023 ASCO Annual Meeting
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
First Author: Suzanne Phillips
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2‑positive cancers.
First Author: Martin Wermke
Poster
2016 ASCO Annual Meeting
Enhanced efficacy and safety of Her2-targeted chimeric antigen receptor (CAR) T cells using MyD88/CD40 costimulation and iCaspase-9 suicide switch.
First Author: Aaron E Foster